Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 25, 2007

Stem Cell Innovations and High Q to Develop Huntington's Disease Models

  • The High Q Foundation and Stem Cell Innovations (SCI) have entered into a two-year R&D alliance. The organizations will apply SCI's PluriCells™ to develop Huntington's-disease-specific human cell systems for the purpose of drug discovery.

    Under the terms of their agreement, SCI will receive up to $1.1 million from High Q upon completion of certain milestones. In addition, SCI has the right to further use, develop, and commercialize the outcome of the project.

    "This agreement will allow us to accelerate our efforts in generating a unique panel of human neurodegenerative disease models, which will be integral in the further development of our potential products," says SCI CEO, James Kelly.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »